Search

everythinglearnresearchcommunity

for

Search:↓

Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.

SOCS3 treatment can prevent hair loss by stopping harmful immune responses.

The 3D-SeboSkin model effectively simulates Hidradenitis suppurativa and is useful for future research.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Gefitinib can cause hair loss without scarring.

Antizyme slows skin tumor growth by reducing cell growth in mice.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.

New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.

SH-340 may improve skin barrier and help treat atopic dermatitis.

The research found enzymes in Stephania epigaea that help make cepharanthine.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Cinchona succirubra extract with caffeine reduces hair loss and strengthens hair.

The absence of functional sebaceous glands causes hair follicle destruction and scarring alopecia.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

MK-386 reduces sebum DHT levels.

Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

EGFR inhibitors can cause unusual localized hair growth.

Antizyme reduces tumor growth and normalizes skin cell development affected by MEK.

AH-001 could be a safer and more effective treatment for hair loss.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

Segmental Vitiligo is a stable, early-onset form of vitiligo that responds well to early treatment and is ideal for repigmentation studies.